Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

[Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].

Rely K, McQuire SE, Alexandre PK, Escudero GS.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S43-7. doi: 10.1016/j.jval.2011.05.033. Spanish.

2.

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.

Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P.

Pharmacoeconomics. 2002;20(13):909-18.

PMID:
12381242
3.

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.

O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P.

Pharmacoeconomics. 2004;22(12):815-25.

PMID:
15294013
4.

Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.

Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.

Clin Ther. 2008 Aug;30(8):1492-504. doi: 10.1016/j.clinthera.2008.07.018.

PMID:
18803991
5.

Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.

Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF.

Pharmacoeconomics. 2006;24(7):695-708. Erratum in: Pharmacoeconomics. 2008;26(10):894.

PMID:
16802845
6.

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.

Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, Gosden T, Rudge H.

Curr Med Res Opin. 2007 May;23(5):1147-59.

PMID:
17519082
7.

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.

O'Connor RD, Stanford R, Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P.

Ann Allergy Asthma Immunol. 2004 Dec;93(6):581-8.

PMID:
15609769
8.
9.

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.

Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S.

Treat Respir Med. 2005;4(2):129-38.

PMID:
15813665
10.

COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.

Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, FitzGerald JM, Su Z.

Respir Med. 2014 Sep;108(9):1292-302. doi: 10.1016/j.rmed.2014.06.005. Epub 2014 Jun 25.

PMID:
25175480
11.
12.

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2003;21(13):951-89. Review.

PMID:
12959627
13.

Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.

Balkrishnan R, Nelsen LM, Kulkarni AS, Pleasants RA, Whitmire JT, Schechter MS.

J Asthma. 2005 Feb;42(1):35-40.

PMID:
15801326
15.

Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.

Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.

J Pediatr. 2005 Aug;147(2):213-20.

PMID:
16126052
16.

Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.

Boonsawat W, Goryachkina L, Jacques L, Frith L.

Clin Drug Investig. 2008;28(2):101-11.

PMID:
18211118
17.

A cost-effectiveness analysis of first-line controller therapies for persistent asthma.

Shih YC, Mauskopf J, Borker R.

Pharmacoeconomics. 2007;25(7):577-90. Review.

PMID:
17610338
18.

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.

Stempel DA, O'Donnell JC, Meyer JW.

J Allergy Clin Immunol. 2002 Mar;109(3):433-9.

PMID:
11897987
19.

Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial.

Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2011 Jan;127(1):161-6, 166.e1. doi: 10.1016/j.jaci.2010.10.035.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk